MedPath

Inimmune's INI-4001 Advances to Human Cancer Trials in Australia

• Inimmune Corporation's INI-4001, a novel cancer treatment compound developed in collaboration with the University of Montana, is moving into human clinical trials in Australia. • The decision to conduct initial trials in Australia was influenced by faster trial initiation processes compared to the United States, with plans to expand to U.S. trials later. • INI-4001 is also being explored for potential use in a vaccine targeting heroin and fentanyl addiction, expanding its therapeutic applications beyond cancer. • The development of INI-4001 was supported by grant funding from the National Institutes of Health, highlighting the importance of research funding in advancing medical breakthroughs.

A cancer treatment compound, INI-4001, developed through a collaboration between the University of Montana and Missoula-based biotech company Inimmune Corporation, is advancing to human clinical trials in Australia. This marks a significant milestone after years of research and grant funding from the National Institutes of Health.
The initial clinical trials will be conducted in Australia, a strategic decision based on the comparatively faster regulatory processes for initiating trials there. Inimmune aims to recruit more patients for the Australian trials before expanding patient recruitment to the United States.
"Research really is a grind. It's slow, it's hard, there's a lot of failures. But those successes when they happen... Those are rewarding and you see the potential is for things that you are working on to help people," said Jay Evans, a researcher from the University of Montana, highlighting both the challenges and rewards of translational research.
Beyond its potential in cancer treatment, INI-4001 is also being investigated for its application in a vaccine targeting heroin and fentanyl addiction. This dual application underscores the broad potential of the compound developed in Missoula.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Dog's Cancer Remission with Tigilanol Tiglate Sparks Hope for Human Trials

A shelter dog named Shandy in Cape Coral experienced complete remission from a mast cell tumor after treatment with Tigilanol Tiglate.
Tigilanol Tiglate, marketed as Stelfonta for veterinary use, is injected directly into the tumor, causing it to die and fall off with minimal downtime.

Akston Biosciences and Purdue University Launch Immunotherapy Trial for Canine Bladder Cancer

Purdue University and Akston Biosciences are trialing an anti-cPD-L1 monoclonal antibody to treat canine urothelial carcinoma.
The immunotherapy aims to enhance the immune system's ability to target and destroy cancer cells in dogs with bladder cancer.

UI researchers receive funding for clinical trials in new cancer treatment - The Daily Iowan

Imugene Doses First Patient in onCARlytics Intratumoral Trial for Solid Tumors

Imugene has dosed the first patient in the intratumoral arm of its Phase 1 OASIS trial, evaluating onCARlytics (CF33-CD19) in combination with blinatumomab.
The OASIS trial is assessing the safety and tolerability of the onCARlytics combination in patients with advanced or metastatic solid tumors.

Cancer Drug Conatumumab Shows Promise in Treating Peripheral Artery Disease

Preclinical studies demonstrate that Conatumumab, previously tested as a cancer drug, effectively treats Peripheral Artery Disease (PAD).
The drug was tested in preclinical models of PAD and in vitro using cells and arteries from PAD patients who underwent amputation.

Monopar Therapeutics Initiates Phase 1a Trial of uPAR-Targeted Radiopharmaceutical MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics has commenced a Phase 1a clinical trial for MNPR-101-Lu, a novel radiopharmaceutical targeting urokinase plasminogen activator receptor (uPAR) in advanced solid tumors.
The open-label, dose-escalation study will initially enroll patients already participating in the MNPR-101-Zr imaging trial to identify those most likely to benefit from the therapy.

IMPDH Inhibition Shows Promise in Preventing Brain Metastasis

Researchers have identified IMPDH as a critical enzyme for cancer cells initiating brain metastases, offering a new therapeutic target.
A library of over 500 molecules has been synthesized and screened, identifying potent inhibitors of IMPDH to halt brain metastasis.

AOH1996: Novel Cancer Drug Selectively Targets Tumors, Spares Healthy Cells in Preclinical Studies

AOH1996, a novel drug developed by City of Hope researchers, targets a unique form of PCNA present in cancer cells, disrupting tumor growth.
Preclinical studies demonstrate AOH1996's efficacy across 70 cancer cell lines, including breast, prostate, lung, and ovarian cancers, without harming healthy cells.

University of Montana's Cancer Immunotherapy Enters Phase 1 Human Trials

Researchers at the University of Montana, in partnership with Inimmune, have advanced a novel cancer treatment into Phase 1 human clinical trials.
The immunotherapy drug, initially developed as an influenza vaccine, aims to retrain the body's immune system to target and destroy cancerous cells.

Fentanyl Vaccine Poised for Clinical Trials, Offering Hope in Opioid Crisis

A fentanyl vaccine developed at the University of Houston is set to enter clinical trials in mid-2025, aiming to prevent the opioid from reaching the brain.
The vaccine uses an adjuvant to stimulate the immune system to produce antibodies against fentanyl, preventing overdose by keeping the drug out of the brain.

Reference News

[1]
Compound discovered at University of Montana making next steps in cancer trials
montanarightnow.com · Oct 7, 2024

University of Montana and Inimmune Corporation advance cancer treatment compound to human trials in Australia, with pote...

[2]
Compound discovered at University of Montana making next steps in cancer trials - KULR-8
kulr8.com · Oct 7, 2024

University of Montana and Inimmune Corporation's cancer treatment compound, INI-4001, advances to human clinical trials ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy